Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**AQT-004**, also known as **MICROTOX**, is an Aquavit Pharmaceuticals drug-device combination product designed for intradermal microchannel delivery of botulinum toxin in aesthetic and dermatologic applications. The proprietary delivery system is intended to distribute botulinum toxin superficially across skin tissue through microchannels, supporting pan-facial microinjection rather than conventional deeper intramuscular neurotoxin injection. The exact botulinum toxin active ingredient, dose, and final marketed formulation have not been publicly specified for AQT-004.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AQT-004.